清疹方对慢性荨麻疹细胞免疫功能的调节作用  

Regulatory Effect of Qingzhenfang on Cellular Immune Function of Patients with Chronic Urticaria

作　　者：罗秋香 梁琼平 尤剑鹏[3] 徐敏玲 梁善秋 LUO Qiu-xiang;LIANG Qiong-ping;YOU Jian-peng;XU Min-ling;LIANG Shan-qiu(Guangri International Zhuang Medical Hospital,Nanning 530000,China;Yao Medical Hospital of Jinxiu Yao Autonomous County,Laibin 545708,China;Guangxi University of Chinese Medicine,Nanning 530000,China)

机构地区：[1]广西国际壮医医院,南宁530000 [2]金秀瑶族自治县瑶医医院,广西来宾545708 [3]广西中医药大学,南宁530000

出　　处：《中国实验方剂学杂志》2021年第4期95-100,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：广西壮族自治区科学技术厅计划项目(桂科AB17195015)。

摘　　要：目的:观察瑶医清疹方对慢性荨麻疹(浆朋比)的临床疗效及对细胞免疫功能的影响作用。方法:按随机数字表法,将132例患者分为对照组和观察组各66例。对照组脱落、失访和剔除共6例,最后完成60例;观察组最后完成62例。两组均口服依巴斯汀片,10~20 mg/次,1次/d。对照组口服皮敏消胶囊,4粒/次,3次/d;观察组内服清疹方,1剂/d。两组疗程均为治疗8周。于治疗前、治疗后2,4,8周分别进行7 d荨麻疹活动度评分(USA7)和皮损情况评分(TSS);进行治疗前后慢性荨麻疹生活质量量表(CU-Q2oL)和风湿热内蕴证评分;对USA7<7分者进行3个月随访,记录复发情况;检测治疗前后补体3,4(C3,C4),CD4^(+)和CD8^(+)细胞,计算Th17,Treg细胞在CD4^(+)细胞中的比例,并计算CD4^(+)/CD8^(+)和Th17/Treg;检测治疗前后外周血白细胞介素-10(IL-10),IL-17,IL-23和IL-35水平;进行安全性评价。结果:在治疗后2,4和8周,观察组USA7评分和TSS评分均低于同期对照组(P<0.01);观察组CU-Q2oL和风湿热内蕴证评分均低于对照组(P<0.01);观察组C3,C4和IL-35水平均高于对照组(P<0.01);观察组CD4^(+),Treg细胞和CD4^(+)/CD8^(+)均高于对照组(P<0.01),观察组IL-10,IL-17,IL-23,CD8^(+),Th17细胞和Th17/Treg均低于对照组(P<0.01);观察组复发率为25.58%(11/43)低于对照组的复发率为48.48%(16/33)(χ^(2)=4.276,P<0.05);观察组临床疗效优于对照组(Z=2.021,P<0.05)。结论:采用清疹方治疗慢性荨麻疹,可控制病情程度,提高生活质量,有着较好的临床疗效,并可减少复发,还能升高C3,C4水平,调节细胞免疫功能,减轻免疫炎症应答,值得临床进一步的研究与使用。Objective: To observe the clinical efficacy of Qingzhenfang for plasmoby(chronic urticaria),and to investigate its effect on cellular immune function. Method: One hundred and thirty-two cases patients were divided into control group and observation group evenly according to random number table.The 60 patients in control group finished the study because of 6 cases of dropout,loss of follow-up and withdrawal,and 62 patients in observation group finished the study. Patients in both groups got Yiebastine tablets,10-20 mg/time,1 time/day. Patients in control group additionally got Piminxiao capsule,4 grains/time,3 times/day,while patients in observation additionally got Qingzhenfang,1 dose/day. The treatment continued for 8 weeks in both groups. Before the treatment,and at the second,fourth,and eighth week after treatment,scores of urticaria activity for 7 days(USA7)and total symptom score(TSS)were graded. Before and after treatment,scores of chronic urticaria quality of life scale(CU-Q2 o L)and syndrome of rheumatic fever were graded. A follow-up of 3 months was conducted for the patients whose score of USA7 was less than 7 to record the recurrence. Complement 3 and 4(C3,C4),CD4^(+),CD8^(+)cells were detected,and Th17/CD4^(+)and Treg/CD4^(+),CD4^(+)/CD8^(+)and Th17/Treg were calculated. Levels of peripheral blood interleukin-10(IL-10),IL-17 and IL-23 were detected,and safety was evaluated after the treatment. Result: At the second,fourth and eighth week after the treatment,scores of USA7,TSS,CU-Q2 o L and syndrome of rheumatic fever in observation group were lower than those in the control group(P<0.01). Levels of C3,C4,CD4^(+),Treg,CD4^(+)/CD8^(+)and IL-35 in observation group were higher than those levels detected in control group(P<0.01),while levels of CD8^(+),Th17,Th17/Treg,IL-10,IL-17 and IL-23 were lower than those in the control group(P<0.01).Recurrence rate was 25.58%(11/43)in observation group,lower than 48.48%(16/33)in control group(χ^(2)=4.276,P<0.05),and the clinical efficacy in observation group was su

关 键 词：慢性荨麻疹(浆朋比) 瑶医 清疹方 补体 细胞免疫 复发 

分 类 号：R289[医药卫生—方剂学] R289.5[医药卫生—中药学]